Weekly Respiratory Research Analysis
This week’s respiratory literature is led by pragmatic diagnostic and organ‑level treatment findings and a robust biomarker study. A multicenter randomized trial (JAMA) shows the YEARS algorithm safely reduces CTPA use in cancer patients with suspected pulmonary embolism. A prospective registry (JAMA) suggests lung transplant can yield favorable early survival in highly selected patients with lung‑limited stage IV NSCLC. A multi‑cohort study (JCI Insight) identifies serum CC16 as a persistent bi
Summary
This week’s respiratory literature is led by pragmatic diagnostic and organ‑level treatment findings and a robust biomarker study. A multicenter randomized trial (JAMA) shows the YEARS algorithm safely reduces CTPA use in cancer patients with suspected pulmonary embolism. A prospective registry (JAMA) suggests lung transplant can yield favorable early survival in highly selected patients with lung‑limited stage IV NSCLC. A multi‑cohort study (JCI Insight) identifies serum CC16 as a persistent biomarker linked to post‑COVID fibrosis‑like CT abnormalities and small‑airway remodeling.
Selected Articles
1. YEARS Algorithm for Diagnosis of Suspected Pulmonary Embolism in Patients With Cancer: A Randomized Clinical Trial.
A multicenter randomized noninferiority trial in 698 patients with active cancer and suspected PE found that the YEARS algorithm was noninferior to a CTPA‑only strategy for 90‑day adjudicated VTE/PE‑related outcomes and allowed omission of CTPA in 22% of patients, with lower event rates after exclusion in the YEARS arm (per‑protocol 1.8% vs 5.5%).
Impact: Fills a key evidence gap by demonstrating a validated, imaging‑sparing diagnostic pathway in a high‑risk oncology population, with immediate implications for guideline updates and radiation/contrast‑exposure reduction.
Clinical Implications: Clinicians can apply the YEARS algorithm in cancer patients with suspected PE to safely reduce CTPA use—decreasing radiation, contrast nephropathy risk, and resource utilization—while maintaining safety through appropriate follow‑up.
Key Findings
- YEARS noninferior to CTPA‑only for 90‑day adjudicated symptomatic VTE/PE or PE‑related death (per‑protocol: 1.8% vs 5.5%; absolute diff −3.7%).
- CTPA was avoided in 22% of patients managed with YEARS.
- Consistent noninferiority in intention‑to‑diagnosis analysis; large multicenter design with blinded central adjudication.
2. Lung Transplant for Refractory Lung-Limited Stage IV Non-Small Cell Lung Cancer.
A prospective single‑center registry compared 17 transplanted patients with lung‑limited, medically refractory stage IV NSCLC to 81 eligible but non‑transplanted patients; 1‑year overall survival in transplant recipients was 100% versus 40.8% in medically managed eligible patients, suggesting lung transplant may confer an early survival advantage in rigorously selected cases.
Impact: Challenges entrenched contraindications by demonstrating feasibility and favorable early survival after lung transplant for selected patients with lung‑limited metastatic NSCLC; could prompt re‑evaluation of transplant candidacy frameworks and multicenter study development.
Clinical Implications: Transplant centers should consider multidisciplinary evaluation pathways for carefully selected lung‑limited stage IV NSCLC patients, but decisions must await longer‑term survival, recurrence, and quality‑of‑life data before broader adoption.
Key Findings
- One‑year overall survival: 100% in transplanted NSCLC (n=17) vs 40.8% in eligible but medically managed NSCLC (n=81).
- One‑year posttransplant survival for NSCLC recipients matched or exceeded non‑cancer transplant recipients (100% vs 88.1%).
- Early follow‑up favorable but longer‑term recurrence and quality‑of‑life data are immature.
3. Pulmonary fibrosis after COVID-19 is characterized by airway abnormalities and elevated club cell secretory protein-16.
In discovery (n=150) and two validation cohorts, higher serum CC16 measured at discharge and at 4, 15, and 36 months post‑hospitalization was consistently associated with fibrosis‑like CT abnormalities. CC16 correlated linearly with airway‑to‑lung ratio and mapped to expansion of SCGB1A1+ and CC16+MUC5B+ small‑airway epithelial cells on scRNA‑seq and immunofluorescence.
Impact: Identifies a longitudinally stable, mechanistically anchored serum biomarker (CC16) that both stratifies risk for persistent fibrosis‑like changes after COVID‑19 and points to airway‑centric biology amenable to targeted interventions and trial enrichment.
Clinical Implications: CC16 could be incorporated into follow‑up algorithms to identify patients who need intensified imaging surveillance or enrollment into trials targeting small‑airway progenitor remodeling; prospective evaluation in diverse populations is warranted.
Key Findings
- Elevated CC16 at discharge, 4, 15, and 36 months associated with fibrosis‑like CT abnormalities in the discovery cohort (n=150) and validated in two external cohorts.
- CC16 levels showed a linear relationship with increased airway‑to‑lung ratio on CT.
- scRNA‑seq and immunofluorescence localized the signal to expansion of SCGB1A1+ and CC16+MUC5B+ epithelial cells in small airways.